Breast Biopsy Market Growing at Remarkable Growth of USD 5.14 Billion by 2032, Key Drivers, Size, Share, Demand and Opportunity Analysis

The global breast biopsy market size reached USD 2.96 Billion in 2022 and is expected to register a revenue CAGR of 5.7% during the forecast period, according to the latest analysis by Emergen Research.

Breast biopsy is a medical procedure that involves the removal of a small amount of breast tissue for examination under a microscope. This procedure is usually performed to diagnose breast cancer or other breast abnormalities. The breast biopsy market is expected to grow significantly in the coming years due to various drivers and growth factors, but also faces some challenges and restraints.

The breast biopsy market is primarily driven by the increasing incidence of breast cancer worldwide. According to the World Health Organization (WHO), breast cancer is the most common cancer among women, with an estimated 2.3 million new cases in 2020. Early detection and diagnosis of breast cancer through biopsy is crucial for better treatment outcomes, leading to an increased demand for breast biopsy procedures. Additionally, technological advancements in biopsy devices, such as the introduction of vacuum-assisted biopsy systems, have also contributed to market growth.

However, the high cost of breast biopsy procedures and the lack of reimbursement policies in some regions act as major restraints for the breast biopsy market. Moreover, the fear and anxiety associated with breast biopsy procedures also hinder the market growth. Patients may be hesitant to undergo the procedure due to the perceived pain and discomfort, leading to delayed diagnosis and treatment.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.emergenresearch.com/request-sample/1718

Despite these challenges, the breast biopsy market is expected to experience significant growth in the coming years, driven by various growth factors. The increasing awareness about breast cancer and the importance of early detection and diagnosis are likely to boost demand for breast biopsy procedures. Moreover, the increasing use of minimally invasive biopsy procedures is also expected to contribute to market growth. These procedures offer several benefits such as reduced pain, shorter recovery times, and lower healthcare costs.

Government organizations also play a significant role in shaping the breast biopsy market. For instance, the American Cancer Society recommends regular mammograms and breast cancer screening for women at average risk. The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides breast and cervical cancer screening services to underserved women in the United States.

Major Companies and Competitive Landscape:

The breast biopsy market is highly competitive, with several players operating in the space. Some of the key players in the market include Devicor Medical Products, Inc., ARGON MEDICAL., B. Braun Melsungen AG, Cardinal Health., Olympus Corporation, Boston Scientific Corporation, FUJIFILM Corporation, INRAD Inc., Medtronic, Hologic, Inc.

Hologic, Inc. is one of the leading players in the breast biopsy market, offering a comprehensive portfolio of biopsy devices, including the Brevera breast biopsy system and the Affirm prone biopsy system. The company has a strong presence in the global market, with a focus on innovation and R&D to develop advanced biopsy technologies.

Becton, Dickinson and Company (BD) is another major player in the breast biopsy market, offering a range of biopsy devices and services, including the BD Vacora biopsy system and BD Core needle biopsy devices. The company has a global presence and is focused on expanding its product portfolio and increasing its market share through strategic partnerships and acquisitions.

F. Hoffmann-La Roche AG is a leading biotechnology company that operates in the breast biopsy market through its subsidiary, Ventana Medical Systems, Inc. The company offers a range of biopsy devices and services, including the Ventana HER2 Dual ISH DNA Probe Cocktail assay for breast cancer diagnosis. The company is focused on innovation and R&D to develop advanced biopsy technologies and expand its market share.

C. R. Bard, Inc., a subsidiary of Becton, Dickinson and Company, offers a range of biopsy devices and services, including the Bard Magnum biopsy system and the Bard Vacuum-Assisted Breast Biopsy (VABB) system. The company has a strong presence in the global market, with a focus on expanding its product portfolio and increasing its market share through strategic partnerships and acquisitions.

Devicor Medical Products, Inc. is a leading provider of biopsy devices and services, including the Mammotome breast biopsy system and the EnCor Enspire breast biopsy system. The company is focused on innovation and R&D to develop advanced biopsy technologies and expand its market share globally.

Request a discount on the report @ https://www.emergenresearch.com/request-discount/1718

Segmentation Insights for Breast Biopsy Market Report:

The breast biopsy market can be segmented based on type, product, and region. In terms of type, the market is divided into mammography, MRI, and others. According to industry reports, the mammography segment accounted for the largest revenue share in 2019 and is expected to continue to dominate the market through 2032.

The market can also be segmented based on product type, which includes vacuum-assisted biopsy, core needle biopsy, and others. The vacuum-assisted biopsy segment is expected to witness significant growth during the forecast period, owing to its advantages over traditional biopsy techniques.

Geographically, the breast biopsy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America, particularly the United States, accounted for the largest revenue share in 2019, due to the high prevalence of breast cancer and the presence of well-established healthcare infrastructure. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, owing to the increasing awareness about breast cancer and the rising demand for advanced diagnostic technologies in countries such as China and India.

View the Full Report Description, the Research Methodology, the Content Table, and the Infographics @ https://www.emergenresearch.com/industry-report/breast-biopsy-market

Eric Lee
Corporate Sales Specialist
14671 110 Avenue, Surrey, British Columbia, V3R2A9
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions.

This release was published on openPR.